Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody
Abstract
The recent Ebola virus outbreak in West Africa illustrates the need for both an effective vaccine and therapies to treat infected individuals. Corti et al. isolated two monoclonal antibodies from a survivor of the 1995 Kikwit outbreak and demonstrated their therapeutic efficacy in Ebola virus–infected macaques. In fact, one antibody protected macaques when it was given up to 5 days after infection. Misasi et al. solved the crystal structures of fragments of the two antibodies bound to the Ebola virus glycoprotein (GP), which mediates viral cell entry. The two antibodies targeted different regions of GP, but in both cases blocked steps required for viral entry.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 18, 2016
- Source ID
- 10.1126/science.aad5224
Entities
People
- Alberto Cagigi
- Antonio Lanzavecchia
- Aurélie Ploquin
- Barney S. Graham
- Blanca Fernandez-rodriguez
- Chiara Silacci
- Daphne A. Stanley
- Davide Corti
- Elisabetta Cameroni
- Emily A. Thompson
- Fabrizia Vanzetta
- Federica Sallusto
- Gloria Agatic
- Hadar Marcus
- Ingelise Gordon
- Jean-jacques Muyembe-tamfun
- John C. Trefry
- John Misasi
- John R. Mascola
- Julie E. Ledgerwood
- Laurent Perez
- Masaru Kanekiyo
- Michael Bailey
- Misook Choe
- Nancy J. Sullivan
- Neville Kisalu
- Nicole A. Doria-rose
- Ryan P. Staupe
- Sabue Mulangu
- Suzanne E Wollen-Roberts
- Wei Shi
Organizations
- ETH Zurich
- United States Army Medical Research Institute of Infectious Diseases
- Università della Svizzera italiana
- Vaccine Research Center